Pediatric pulmonology · 2025
Late Permissive Hypercapnia for Mechanically Ventilated Preterm Infants: A Randomized Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Travers Colm P, Gentle Samuel J, Shukla Vivek V, Aban Inmaculada, Yee Aaron J, Armstead Kimberly M, Benz Rachel L, Laney Deborah, Ambalavanan Namasivayam, Carlo Waldemar A
Аннотация
OBJECTIVE: To determine if targeting higher levels of pH-controlled permissive hypercapnia beyond postnatal day 7-14 reduces mechanical ventilation duration in preterm infants.
METHODS: Single-center randomized clinical trial with a 1:1 parallel allocation including infants from 22-36 weeks' gestation mechanically ventilated for respiratory distress syndrome on postnatal day 7-14. We targeted higher levels of pH-controlled permissive hypercapnia (60-75 mmHg and pH ≥ 7.20) or lower levels of pH-controlled permissive hypercapnia (40-55 mmHg and pH ≥ 7.25) for 28 days after randomization. The primary outcome was the number of days alive and ventilator-free in the 28 days after randomization.
RESULTS: We enrolled 130 infants with a gestational age (mean ± SD) of 24 weeks and 5 days ± 2 weeks and 0 days and birth weight of 657 ± 198 grams from December 2015 to May 2021. Infants randomized to higher levels of pH-controlled permissive hypercapnia had more alive ventilator-free days than infants randomized to lower levels of pH-controlled permissive hypercapnia (11 ± 10 vs. 6 ± 8; p = 0.009). Grade 2-3 bronchopulmonary dysplasia or death before discharge was not significantly lower in the higher carbon dioxide (PCO2) group (30/62 (44%) vs. 45/68 (59%); adjusted odds ratio (aOR) 0.54, 95% confidence intervals (CI) 0.27-1.08; p = 0.08). Grade 2-3 bronchopulmonary dysplasia among survivors at 36 weeks' postmenstrual age did not differ significantly (higher PCO2 19/53 (35%) vs. lower PCO2 28/53 (50%); aOR 0.56, 95% CI 0.27-1.13; p = 0.12).
CONCLUSIONS: Targeting higher levels of permissive hypercapnia from postnatal day 7-14 increased the number of days alive and ventilator-free and may be lung protective compared with targeting lower levels.
TRIAL REGISTRATION: Clinicaltrials.gov (identifier number NCT02799875). The first infant was enrolled in December 2015 and the trial was not registered until June 2016. The authors confirm that there were no changes made to the Institutional Review Board (IRB) approved trial protocol (dated 10/20/2015) or any amendments made after recruitment started, between the date of first enrollment and the date of clinicaltrials.gov registration, or between study commencement and completion. Furthermore, the authors confirm that the data were not unblinded until after the last infant had been enrolled (March 2021) and discharged from the hospital (August 2021). Study Details | Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants | ClinicalTrials.gov.
METHODS: Single-center randomized clinical trial with a 1:1 parallel allocation including infants from 22-36 weeks' gestation mechanically ventilated for respiratory distress syndrome on postnatal day 7-14. We targeted higher levels of pH-controlled permissive hypercapnia (60-75 mmHg and pH ≥ 7.20) or lower levels of pH-controlled permissive hypercapnia (40-55 mmHg and pH ≥ 7.25) for 28 days after randomization. The primary outcome was the number of days alive and ventilator-free in the 28 days after randomization.
RESULTS: We enrolled 130 infants with a gestational age (mean ± SD) of 24 weeks and 5 days ± 2 weeks and 0 days and birth weight of 657 ± 198 grams from December 2015 to May 2021. Infants randomized to higher levels of pH-controlled permissive hypercapnia had more alive ventilator-free days than infants randomized to lower levels of pH-controlled permissive hypercapnia (11 ± 10 vs. 6 ± 8; p = 0.009). Grade 2-3 bronchopulmonary dysplasia or death before discharge was not significantly lower in the higher carbon dioxide (PCO2) group (30/62 (44%) vs. 45/68 (59%); adjusted odds ratio (aOR) 0.54, 95% confidence intervals (CI) 0.27-1.08; p = 0.08). Grade 2-3 bronchopulmonary dysplasia among survivors at 36 weeks' postmenstrual age did not differ significantly (higher PCO2 19/53 (35%) vs. lower PCO2 28/53 (50%); aOR 0.56, 95% CI 0.27-1.13; p = 0.12).
CONCLUSIONS: Targeting higher levels of permissive hypercapnia from postnatal day 7-14 increased the number of days alive and ventilator-free and may be lung protective compared with targeting lower levels.
TRIAL REGISTRATION: Clinicaltrials.gov (identifier number NCT02799875). The first infant was enrolled in December 2015 and the trial was not registered until June 2016. The authors confirm that there were no changes made to the Institutional Review Board (IRB) approved trial protocol (dated 10/20/2015) or any amendments made after recruitment started, between the date of first enrollment and the date of clinicaltrials.gov registration, or between study commencement and completion. Furthermore, the authors confirm that the data were not unblinded until after the last infant had been enrolled (March 2021) and discharged from the hospital (August 2021). Study Details | Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants | ClinicalTrials.gov.